Page 210 - Read Online

Page 706 Alonso-Peña et al. Cancer Drug Resist 2019;2:680-709 I http://dx.doi.org/10.20517/cdr.2019.006

Toxicol Sci 2006;90:5-22.
107. Brandon EF, Sparidans RW, Meijerman I, Manzanares I, Beijnen JH, et al. In vitro characterization of the biotransformation of
thiocoraline, a novel marine anti-cancer drug. Invest New Drugs 2004;22:241-51.
108. Fernandez-Santander A, Gaibar M, Novillo A, Romero-Lorca A, Rubio M, et al. Relationship between genotypes Sult1a2 and Cyp2d6
and tamoxifen metabolism in breast cancer patients. PLoS One 2013;8:e70183.
109. Lu L, Zhou J, Shi J, Peng XJ, Qi XX, et al. Drug-metabolizing activity, protein and gene expression of udp-glucuronosyltransferases are
significantly altered in hepatocellular carcinoma patients. PLoS One 2015;10:e0127524.
110. Ye L, Yang X, Guo E, Chen W, Lu L, et al. Sorafenib metabolism is significantly altered in the liver tumor tissue of hepatocellular
carcinoma patient. PLoS One 2014;9:e96664.
111. Hu DG, Mackenzie PI, Lu L, Meech R, McKinnon RA. Induction of human UDP-Glucuronosyltransferase 2B7 gene expression by
cytotoxic anticancer drugs in liver cancer HepG2 cells. Drug Metab Dispos 2015;43:660-8.
112. Zahreddine HA, Borden KL. Molecular pathways: GLI1-induced drug glucuronidation in resistant cancer cells. Clin Cancer Res
2015;21:2207-10.
113. Marin JJ, Romero MR, Martinez-Becerra P, Herraez E, Briz O. Overview of the molecular bases of resistance to chemotherapy in liver
and gastrointestinal tumours. Curr Mol Med 2009;9:1108-29.
114. Zheng YB, Zhan MX, Zhao W, Liu B, Huang JW, et al. The relationship of kinase insert domain receptor gene polymorphisms and
clinical outcome in advanced hepatocellular carcinoma patients treated with sorafenib. Med Oncol 2014;31:209.
115. Jain L, Sissung TM, Danesi R, Kohn EC, Dahut WL, et al. Hypertension and hand-foot skin reactions related to VEGFR2 genotype and
improved clinical outcome following bevacizumab and sorafenib. J Exp Clin Cancer Res 2010;29:95.
116. Hansen TF, Garm Spindler KL, Andersen RF, Lindebjerg J, Brandslund I, et al. The predictive value of genetic variations in the vascular
endothelial growth factor A gene in metastatic colorectal cancer. Pharmacogenomics J 2011;11:53-60.
117. Orlandi P, Fontana A, Fioravanti A, Di Desidero T, Galli L, et al. VEGF-A polymorphisms predict progression-free survival among
advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide. Br J Cancer 2013;109:957-64.
118. Scartozzi M, Faloppi L, Svegliati Baroni G, Loretelli C, Piscaglia F, et al. VEGF and VEGFR genotyping in the prediction of clinical
outcome for HCC patients receiving sorafenib: the ALICE-1 study. Int J Cancer 2014;135:1247-56.
119. Schulze K, Imbeaud S, Letouze E, Alexandrov LB, Calderaro J, et al. Exome sequencing of hepatocellular carcinomas identifies new
mutational signatures and potential therapeutic targets. Nat Genet 2015;47:505-11.
120. Robertson S, Hyder O, Dodson R, Nayar SK, Poling J, et al. The frequency of KRAS and BRAF mutations in intrahepatic
cholangiocarcinomas and their correlation with clinical outcome. Hum Pathol 2013;44:2768-73.
121. Angkathunyakul N, Rosini F, Heaton N, Foskett P, Quaglia A. BRAF V600E mutation in biliary proliferations associated with alpha1-
antitrypsin deficiency. Histopathology 2017;70:485-91.
122. Dow M, Pyke RM, Tsui BY, Alexandrov LB, Nakagawa H, et al. Integrative genomic analysis of mouse and human hepatocellular
carcinoma. Proc Natl Acad Sci U S A 2018;115:E9879-E88.
123. Yamamoto M, Tanaka H, Xin B, Nishikawa Y, Yamazaki K, et al. Role of the BrafV637E mutation in hepatocarcinogenesis induced by
treatment with diethylnitrosamine in neonatal B6C3F1 mice. Mol Carcinog 2017;56:478-88.
124. Crystal AS, Shaw AT, Sequist LV, Friboulet L, Niederst MJ, et al. Patient-derived models of acquired resistance can identify effective
drug combinations for cancer. Science 2014;346:1480-6.
125. Bean J, Brennan C, Shih JY, Riely G, Viale A, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung
tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 2007;104:20932-7.
126. Dong LQ, Shi Y, Ma LJ, Yang LX, Wang XY, et al. Spatial and temporal clonal evolution of intrahepatic cholangiocarcinoma. J Hepatol
2018;69:89-98.
127. Rad R, Cadinanos J, Rad L, Varela I, Strong A, et al. A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis
reveals targets for therapeutic intervention. Cancer Cell 2013;24:15-29.
128. Aboussekhra A, Biggerstaff M, Shivji MK, Vilpo JA, Moncollin V, et al. Mammalian DNA nucleotide excision repair reconstituted with
purified protein components. Cell 1995;80:859-68.
129. Zhou W, Gurubhagavatula S, Liu G, Park S, Neuberg DS, et al. Excision repair cross-complementation group 1 polymorphism
predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res
2004;10:4939-43.
130. Gurubhagavatula S, Liu G, Park S, Zhou W, Su L, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced
non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 2004;22:2594-601.
131. Yang Z, Zhao J. Effect of APE1 and XRCC1 gene polymorphism on susceptibility to hepatocellular carcinoma and sensitivity to
cisplatin. Int J Clin Exp Med 2015;8:9931-6.
132. Golan T, Raitses-Gurevich M, Kelley RK, Bocobo AG, Borgida A, et al. Overall Survival and Clinical Characteristics of BRCA-
Associated Cholangiocarcinoma: A Multicenter Retrospective Study. Oncologist 2017;22:804-10.
133. Wardell CP, Fujita M, Yamada T, Simbolo M, Fassan M, et al. Genomic characterization of biliary tract cancers identifies driver genes
and predisposing mutations. J Hepatol 2018;68:959-69.
134. Zimmer AS, Gillard M, Lipkowitz S, Lee JM. Update on PARP Inhibitors in Breast Cancer. Curr Treat Options Oncol 2018;19:21.
135. Ueda S, Shirabe K, Morita K, Umeda K, Kayashima H, et al. Evaluation of ERCC1 expression for cisplatin sensitivity in human
hepatocellular carcinoma. Ann Surg Oncol 2011;18:1204-11.
136. Fautrel A, Andrieux L, Musso O, Boudjema K, Guillouzo A, et al. Overexpression of the two nucleotide excision repair genes ERCC1